[Involvement of chymase in angiogenesis in hamster sponge granulomas].
We investigated the angiogenic effect of chymase, an alternative angiotensin II-generating enzyme, on angiogenesis using hamster sponge implant model. Exogenous administration of angiotensin II (Ang II) or angiotensin I (Ang I) directly into the sponges enhanced angiogenesis, as determined from the hemoglobin contents in the sponge granuloma tissues. Chymostatin, an inhibitor of chymase, inhibited angiogenesis induced by Ang I but not by Ang II, suggesting the presence of a chymase-like Ang II-generating activity in the sponge granuloma. TCV-116 (5 mg/kg p.o.), an antagonist of Ang II type 1 receptor, and chymostatin suppressed bFGF-induced angiogenesis, suggesting the significance of the endogenous angiotensin system. Chymase activity in the sponge granuloma increased in parallel with the rise in hemoglobin contents induced by bFGF. We also examined the effects of direct administration of human pro-chymase gene or purified hamster chymase, and demonstrated that in vivo human pro-chymase gene transfection and direct injection of purified chymase enhanced angiogenesis, which was 50% inhibited by TCV-116. Sponge granulomas treated with Ang II was supressed by vascular endothelial growth factor (VEGF) antisense. Our results suggest that chymase enhanced angiogenesis partly through the local production of Ang II, followed by up-regulation of VEGF.
Muramatsu
M
M
Department of Pharmacology, Kitasato University School of Medicine, Kanagawa, Japan.
Katada
J
J
Hayashi
I
I
Majima
M
M
D000803:Angiotensin I / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000494:pharmacology; D053818:Chymases; D002918:Chymotrypsin / Q000037:antagonists & inhibitors; D006224:Cricetinae; D016228:Endothelial Growth Factors / Q000494:pharmacology; D006099:Granuloma / Q000473:pathology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008222:Lymphokines / Q000494:pharmacology; D008297:Male; D008647:Mesocricetus; D018919:Neovascularization, Physiologic / Q000502:physiology*; D009842:Oligopeptides / Q000494:pharmacology; D020033:Protein Isoforms; D012697:Serine Endopeptidases / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D013777:Tetrazoles; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D016228:Endothelial Growth Factors; D006454:Hemoglobins; D008222:Lymphokines; D009842:Oligopeptides; D020033:Protein Isoforms; D015842:Serine Proteinase Inhibitors; D013777:Tetrazoles; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000804:Angiotensin II; D000803:Angiotensin I; C002101:chymostatin; D012697:Serine Endopeptidases; D002918:Chymotrypsin; D053818:Chymases; C077793:candesartan cilexetil